Terms: = Germ cell tumor AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Staging
16 results:
1. Midkine Promotes Metastasis and Therapeutic Resistance via mtor/RPS6 in Uveal Melanoma.
Karg MM; John L; Refaian N; Buettner C; Rottmar T; Sommer J; Bock B; Resheq YJ; Ksander BR; Heindl LM; Mackensen A; Bosch JJ
Mol Cancer Res; 2022 Aug; 20(8):1320-1336. PubMed ID: 35503453
[TBL] [Abstract] [Full Text] [Related]
2. Merkel cell Carcinoma from Molecular Pathology to Novel Therapies.
Stachyra K; Dudzisz-Śledź M; Bylina E; Szumera-Ciećkiewicz A; Spałek MJ; Bartnik E; Rutkowski P; Czarnecka AM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208339
[TBL] [Abstract] [Full Text] [Related]
3. Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies.
Arakelyan J; Zohrabyan D; Philip PA
Cancer; 2021 Feb; 127(3):345-353. PubMed ID: 33270905
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive Investigation into the Role of Ubiquitin-Conjugating Enzyme E2S in Melanoma Development.
Wang P; Li Y; Ma Y; Zhang X; Li Z; Yu W; Zhu M; Wang J; Xu Y; Xu A
J Invest Dermatol; 2021 Feb; 141(2):374-384. PubMed ID: 32603752
[TBL] [Abstract] [Full Text] [Related]
5. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.
Lee L; Ito T; Jensen RT
Expert Opin Pharmacother; 2018 Jun; 19(8):909-928. PubMed ID: 29757017
[TBL] [Abstract] [Full Text] [Related]
6. Merkel cell Carcinoma Therapeutic Update.
Cassler NM; Merrill D; Bichakjian CK; Brownell I
Curr Treat Options Oncol; 2016 Jul; 17(7):36. PubMed ID: 27262710
[TBL] [Abstract] [Full Text] [Related]
7. [What is new in the pathology of pancreatic neuroendocrine tumors?].
Komminoth P; Perren A
Pathologe; 2015 May; 36(3):220-8. PubMed ID: 25941099
[TBL] [Abstract] [Full Text] [Related]
8. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
Santhanam P; Taïeb D
Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
[TBL] [Abstract] [Full Text] [Related]
9. PI3K-AKT-mtor-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms.
Briest F; Grabowski P
Theranostics; 2014; 4(4):336-65. PubMed ID: 24578720
[TBL] [Abstract] [Full Text] [Related]
10. Pilocytic astrocytoma: a review of genetic and molecular factors, diagnostic and prognostic markers.
Bikowska-Opalach B; Szlufik S; Grajkowska W; Jozwiak J
Histol Histopathol; 2014 Oct; 29(10):1235-48. PubMed ID: 24554201
[TBL] [Abstract] [Full Text] [Related]
11. Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors.
Komori Y; Yada K; Ohta M; Uchida H; Iwashita Y; Fukuzawa K; Kashima K; Yokoyama S; Inomata M; Kitano S
J Hepatobiliary Pancreat Sci; 2014 Apr; 21(4):288-95. PubMed ID: 24002888
[TBL] [Abstract] [Full Text] [Related]
12. Expression of PTEN and mtor in pancreatic neuroendocrine tumors.
Han X; Ji Y; Zhao J; Xu X; Lou W
Tumour Biol; 2013 Oct; 34(5):2871-9. PubMed ID: 23686804
[TBL] [Abstract] [Full Text] [Related]
13. Neuroendocrine tumours of the small intestine.
Strosberg J
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):755-73. PubMed ID: 23582917
[TBL] [Abstract] [Full Text] [Related]
14. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.
Oberg K
Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940
[TBL] [Abstract] [Full Text] [Related]
15. Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.
Alexandraki KI; Kaltsas G
Endocrine; 2012 Feb; 41(1):40-52. PubMed ID: 22124940
[TBL] [Abstract] [Full Text] [Related]
16. Current treatment options for neuroendocrine tumors.
Hörsch D; Grabowski P; Schneider CP; Petrovitch A; Kaemmerer D; Hommann M; Baum RP
Drugs Today (Barc); 2011 Oct; 47(10):773-86. PubMed ID: 22076492
[TBL] [Abstract] [Full Text] [Related]
